tracon
report
third
quarter
financial
results
company
highlights
november
san
diego
globe
newswire
tracon
pharmaceuticals
nasdaq
tcon
clinical
stage
biopharmaceutical
company
focused
development
commercialization
novel
targeted
cancer
therapeutics
utilizing
cost
efficient
product
development
platform
partner
companies
develop
commercialize
innovative
products
announced
today
report
third
quarter
financial
operating
results
close
financial
markets
tuesday
november
addition
management
host
conference
call
provide
update
corporate
activities
discuss
quarterly
financial
results
conference
call
webcast
date
november
time
pm
eastern
time
pm
pacific
time
domestic
international
passcode
via
web
events
presentations
section
within
investors
section
replay
webcast
available
days
website
tracon
tracon
develops
targeted
therapies
cancer
utilizing
capital
efficient
cro
independent
product
development
platform
company
pipeline
includes
envafolimab
subcutaneous
antibody
developed
treatment
sarcoma
goal
initiating
pivotal
trial
second
half
small
molecule
drug
candidate
treatment
prostate
cancer
phase
small
molecule
drug
candidate
developed
treatment
lung
cancer
antibody
phase
development
treatment
advanced
solid
tumors
tracon
actively
seeking
additional
corporate
partnerships
whereby
leads
regulatory
clinical
development
shares
cost
risk
clinical
development
leads
commercialization
partnerships
tracon
believes
serve
solution
companies
without
clinical
commercial
capabilities
learn
tracon
product
pipeline
visit
tracon
website
company
contact
investor
contact
mark
wiggins
brian
ritchie
chief
business
officer
lifesci
advisors
llc
mwiggins
britchie
